Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5473 - A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Thyroid Cancer


Jolanta Krajewska


Annals of Oncology (2018) 29 (suppl_8): viii645-viii648. 10.1093/annonc/mdy302


J. Krajewska1, B.G. Robinson2, B. Keam3, J. Capdevila Castillon4, A. Klochikhin5, H. Gan6, E. Kapiteijn7, R. Elisei8, J. Partyka9, A.E. Borgman9, M. Schlumberger10

Author affiliations

  • 1 Oncology Center, M. Sklodowska-Curie Institute, 44-101 - Gliwice/PL
  • 2 Sydney Medical School, The University of Sydney, Sydney/AU
  • 3 Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 4 Gastrointestinal And Endocrine Tumor Unit, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 5 Oncology, Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl/RU
  • 6 Clinical Trials Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg/AU
  • 7 Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 8 Endocrine Unit, University Hospital of Pisa, Pisa/IT
  • 9 Clinical research & Development, Exelixis, Inc, San Francisco/US
  • 10 Department Of Nuclear Medicine And Endocrine Oncology, Gustave Roussy, Villejuif/FR

Abstract 5473


C inhibits receptor tyrosine kinases including MET, VEGF receptors, AXL, and RET. C has been approved in the US for the treatment of progressive, metastatic MTC and in the EU for progressive, unresectable locally advanced or metastatic MTC. In the phase 3 registrational study EXAM, pts were randomized 2:1 to receive 140 mg C or placebo (P) once daily (qd). The primary analysis for EXAM demonstrated a statistically significant improvement in progression-free survival (PFS) with a median PFS of 11.2 mo for C vs 4.0 mo for P (hazard ratio [HR] 0.28, 95% CI, 0.19–0.40; p < 0.001) (Elisei, JCO 2013). Dose reductions occurred commonly in the C arm with 82% of pts experiencing at least one dose reduction. While overall survival (OS) was not significantly improved in the overall population (median OS of 26.6 mo for C vs 21.1 mo for P; HR 0.85, 95% CI 0.64–1.12; p = 0.24), median OS was 44.3 mo for C vs 18.9 mo for P (HR 0.60, 95% CI 0.38–0.94) in the RET M918T-positive subgroup (Schlumberger, Ann Oncol 2017).

Trial design

EXAMINER (NCT01896479) is a global, randomized, double-blind study comparing the safety and efficacy of C at 60 vs 140 mg qd in pts with progressive, metastatic MTC using a noninferiority study design. Approximately 188 pts will be randomized 1:1 to receive C at 140 mg qd as capsules or 60 mg qd as tablets in Europe, Asia, Canada, and other regions. Eligible pts must have measurable disease and documented progressive disease within 14 mo prior to enrollment. A recent tumor tissue sample to test for RET and RAS mutations or documentation of a RET or RAS mutation is required. Pts will be stratified based on RET M918T status. After randomization, pts will be treated until disease progression per RECIST 1.1 or intolerable toxicity. Tumor assessments will be performed every 12 weeks. PFS and objective response rate evaluated by independent review are the primary and secondary efficacy endpoints, respectively; safety and correlation of tumor mutation status with clinical response are additional endpoints. The EXAMINER study continues to enroll pts.

Clinical trial identification


Legal entity responsible for the study

Exelixis, Inc.


The study was supported by Exelixis, Inc.

Editorial Acknowledgement


J. Krajewska: Honoraria and subinvestigator in clinical trials: Eisai, Exelixis, Sanofi-Genzyme, Bayer Health Care; Travel, accommodations, expenses: Sanofi-Genzyme, Ipsen, Novartis. B.G. Robinson: Stock or other ownership: Cochlear Ltd.; Honoraria, consulting or advisory role, speakers' bureau: Eisai; Travel, accommodations, expenses: Loxo. H. Gan: Consulting or advisory role: MSD, AbbVie; Speakers' bureau, travel, accommodations, expenses: Ignyta; Research funding: BMS, Ignyta. R. Elisei: Consulting or advisory role: Sanofi-Genzyme, Eisai, Loxo, Exelixis; Speakers' bureau: Sanofi-Genzyme, Eisai; Travel, accommodations, expenses: Sanofi-Genzyme. J. Partyka: Employment, research funding, travel, accommodations and expenses, stock or other ownership: Exelixis. A.E. Borgman: Employee, stock or other ownership: Exelixis. M. Schlumberger: Honoraria, research funding: Bayer, Eisai, Exelixis-Ipsen, Sanofi-Genzyme; Consulting or advisory role: Bayer, Eisai, Exelixis-Ipsen, Sanofi-Genzyme; Travel, accommodations, expenses: Bayer, Eisai, Sanofi-Genzyme. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.